Impact of use of newer glucose lowering drugs on outcomes in patients with COVID-19

Study identification

• EU PAS number:
  EUPAS36089
• Study ID:
  40215
• Official title and acronym:
  Impact of use of newer glucose lowering drugs on outcomes in patients with COVID-19
• DARWIN EU® study:
  No
• Study countries:
  Denmark
• Study description:
  The coronavirus disease 2019 (COVID-19) pandemic poses great health care challenges worldwide. In Denmark, authority regulated social distancing has been the key to limit rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) keeping the diseased population below the tolerable threshold. However, the COVID-19 epidemic is expected to return in one or more waves which emphasizes the need for identifying modifiable risk factors in vulnerable patients. Newer glucose lowering drugs (GLD) have potential for affecting the disease course by suppressing the inflammatory state or by upregulation of the angiotensin-converting enzyme 2 (ACE2). The study is a national cohort study on patients tested positive for SARS-CoV-2 in Denmark. This study will examine the association between ongoing use of newer glucose-lowering drugs (Glucagon Like Peptid-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase-4 (DPP4) inihibitors and Sodium-Glucose Transport Protein-2 (SGLT2) inhibitors) and other glucose lowering drugs and risk of severe outcomes in COVID-19 patients. Severe outcomes include hospital admission, intensive care unit (ICU) admission, mechanical ventilation and death within 30 days from positive SARS-CoV-2 test.
• Study status:
  Finalised

Research institutions and networks

Institutions

Pharmacoepi center, University of Southern Denmark

Denmark

Department of Clinical Epidemiology Aarhus University Hospital, Aarhus, Denmark, Center for Research and Disruption in Infectious Diseases, Department of Infectious Diseases Amager Hvidovre Hospital, Hvidovre, Denmark

Study timelines

Date when funding contract was signed

Actual:22/04/2020

Study start date

Actual:27/02/2020

Data analysis start date

Planned:01/07/2020

Date of final study report

Planned:01/10/2020

Actual:13/01/2021

Sources of funding

No external funding

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable